Drug profile

The FDA adverse-event record for Osurnia

11 FDA reports name Osurnia, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2489 of 2,679
by report volume (all drugs)
11
adverse-event reports
9.1%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Osurnia ranks #2412 of 2679 by total reports (11). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2412
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Signature read: 11 reports place Osurnia in the lower third of FDA AER volume (#2489 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
1
Deaths Reported
9.1%
Death-coded share of reports

Active Ingredients

Osurnia

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 9
Cat 2

Most Affected Breeds

Shih Tzu 2
Retriever - Golden 2
Bulldog - American 1
Terrier (unspecified) 1
Shepherd Dog - Australian 1
Domestic Longhair 1
Domestic Shorthair 1
Retriever - Labrador 1
Chihuahua 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 3
Elevated lipase 3
Vomiting 2
Inappropriate urination 2
Weight loss 2
Blood in vomit 2
Intentional misuse 2
Head tremor 1
Diarrhoea 1
Liver failure 1
Death by euthanasia 1
Polyuria 1

Outcome Breakdown

Ongoing
5 (45.5%)
Recovered/Normal
5 (45.5%)
Euthanized
1 (9.1%)

Osurnia: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Osurnia (#2489 of 2,679 by report volume); death-coded 9.1%. PlainBreed drug row · report volume stamp 11 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →